Current status of antiretroviral therapy

Zelalem Temesgen; David Warnke; Mary J. Kasten

doi:10.1517/14656566.7.12.1541

Current status of antiretroviral therapy

Zelalem Temesgen, David Warnke, Mary J. Kasten

Infectious Diseases

Research output: Contribution to journal › Review article › peer-review

68 Scopus citations

Abstract

At present, there are 22 FDA-approved antiretroviral agents, which are categorised into four classes of drugs. Several others are in various stages of basic and clinical development. The authors of this paper review the general characteristics of each class of antiretrovirals, as well as individual investigational agents that are in advanced clinical development. A brief synopsis of US and WHO antiretroviral treatment guidelines is also provided.

Original language	English (US)
Pages (from-to)	1541-1554
Number of pages	14
Journal	Expert Opinion on Pharmacotherapy
Volume	7
Issue number	12
DOIs	https://doi.org/10.1517/14656566.7.12.1541
State	Published - Aug 2006

Keywords

Antiretroviral therapy
Antiretrovirals
Chemokine receptor antagonists
Entry inhibitors
Fusion inhibitors
HIV
Highly active antiretroviral therapy
Integrase inhibitors
Maturation inhibitors
Non-nucleoside analogue reverse transcriptase inhibitors
Nucleoside analogue reverse transcriptase inhibitors
Protease inhibitors
Treatment guidelines

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1517/14656566.7.12.1541

Cite this

@article{b25533effef44c3682a7c7271c531d1f,

title = "Current status of antiretroviral therapy",

abstract = "At present, there are 22 FDA-approved antiretroviral agents, which are categorised into four classes of drugs. Several others are in various stages of basic and clinical development. The authors of this paper review the general characteristics of each class of antiretrovirals, as well as individual investigational agents that are in advanced clinical development. A brief synopsis of US and WHO antiretroviral treatment guidelines is also provided.",

keywords = "Antiretroviral therapy, Antiretrovirals, Chemokine receptor antagonists, Entry inhibitors, Fusion inhibitors, HIV, Highly active antiretroviral therapy, Integrase inhibitors, Maturation inhibitors, Non-nucleoside analogue reverse transcriptase inhibitors, Nucleoside analogue reverse transcriptase inhibitors, Protease inhibitors, Treatment guidelines",

author = "Zelalem Temesgen and David Warnke and Kasten, {Mary J.}",

year = "2006",

month = aug,

doi = "10.1517/14656566.7.12.1541",

language = "English (US)",

volume = "7",

pages = "1541--1554",

journal = "Expert Opinion on Pharmacotherapy",

issn = "1465-6566",

publisher = "Informa Healthcare",

number = "12",

}

TY - JOUR

T1 - Current status of antiretroviral therapy

AU - Temesgen, Zelalem

AU - Warnke, David

AU - Kasten, Mary J.

PY - 2006/8

Y1 - 2006/8

N2 - At present, there are 22 FDA-approved antiretroviral agents, which are categorised into four classes of drugs. Several others are in various stages of basic and clinical development. The authors of this paper review the general characteristics of each class of antiretrovirals, as well as individual investigational agents that are in advanced clinical development. A brief synopsis of US and WHO antiretroviral treatment guidelines is also provided.

AB - At present, there are 22 FDA-approved antiretroviral agents, which are categorised into four classes of drugs. Several others are in various stages of basic and clinical development. The authors of this paper review the general characteristics of each class of antiretrovirals, as well as individual investigational agents that are in advanced clinical development. A brief synopsis of US and WHO antiretroviral treatment guidelines is also provided.

KW - Antiretroviral therapy

KW - Antiretrovirals

KW - Chemokine receptor antagonists

KW - Entry inhibitors

KW - Fusion inhibitors

KW - HIV

KW - Highly active antiretroviral therapy

KW - Integrase inhibitors

KW - Maturation inhibitors

KW - Non-nucleoside analogue reverse transcriptase inhibitors

KW - Nucleoside analogue reverse transcriptase inhibitors

KW - Protease inhibitors

KW - Treatment guidelines

UR - http://www.scopus.com/inward/record.url?scp=33747078251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747078251&partnerID=8YFLogxK

U2 - 10.1517/14656566.7.12.1541

DO - 10.1517/14656566.7.12.1541

M3 - Review article

C2 - 16872258

AN - SCOPUS:33747078251

SN - 1465-6566

VL - 7

SP - 1541

EP - 1554

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

IS - 12

ER -

Current status of antiretroviral therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this